Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $27,675.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 1,107 shares of Enliven Therapeutics stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $25.00, for a total transaction of $27,675.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Thursday, May 9th, Anish Patel sold 260 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.06, for a total value of $6,515.60.
• On Monday, May 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.72, for a total transaction of $110,760.00.
• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.03, for a total value of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total value of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.64, for a total value of $76,245.00.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $23.04 on Friday. The company’s fifty day moving average is $18.77 and its 200 day moving average is $15.43. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the stock. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the 4th quarter worth $28,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $66,000. Exchange Traded Concepts LLC lifted its stake in Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after acquiring an additional 2,208 shares during the period. SG Americas Securities LLC bought a new position in Enliven Therapeutics during the 3rd quarter worth about $157,000. Finally, EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the 1st quarter worth about $167,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.